Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

被引：29

作者：

Van Baelen, Kurt ^{[1
]}

Van Eygen, Veerle ^{[1
]}

Rondelez, Evelien ^{[1
]}

Stuyver, Lieven J. ^{[1
]}

机构：

[1] Virco BVBA, B-2800 Mechelen, Belgium

来源：

AIDS | 2008年 / 22卷 / 14期

关键词：

D O I：

10.1097/QAD.0b013e32830f9703

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.

引用

页码：1877 / 1880

页数：4

共 50 条

[31] Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
Nguyen, Bach-Yen T.
Isaacs, Robin D.
Teppler, Hedy
Leavitt, Randi Y.
Sklar, Peter
Iwamoto, Marian
Wenning, Larissa A.
Miller, Michael D.
Chen, Joshua
Kemp, Ramon
Xu, Wei
Fromtling, Robert A.
Vacca, Joseph P.
Young, Steven D.
Rowley, Michael
Lower, Michael W.
Gottesdiener, Keith M.
Hazuda, Daria J.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010, 2011, 1222 : 83 - 89
[32] The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates
Jose Buzon, Maria
Dalmau, Judith
Carmen Puertas, Maria
Puig, Jordi
Clotet, Bonaventura
Martinez-Picado, Javier
AIDS, 2010, 24 (01) : 17 - 25
[33] Resistance associated mutations in HIV-1 subtype C primary viruses after in vitro passage with integrase inhibitors raltegravir, elvitegravir and dolutegravir
Mphahlele, M.
Hewer, R.
Bronze, M.
Travers, S. A. A.
Mosebi, S.
Steegen, K.
Carmona, S.
Stevens, W. S.
Papathanasopoulos, M. A.
ANTIVIRAL THERAPY, 2013, 18 : A102 - A102
[34] Raltegravir (MK-0518): An integrase inhibitor for the treatment of HIV-1
Evering, Teresa Hope
Markowitz, Martin
DRUGS OF TODAY, 2007, 43 (12) : 865 - 877
[35] Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness
Hu, Zixin
Kuritzkes, Daniel R.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (02) : 148 - 155
[36] Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients
Fukada, K
Tomiyama, H
Wasi, C
Matsuda, T
Kusagawa, S
Sato, H
Oka, S
Takebe, Y
Takiguchi, M
AIDS, 2002, 16 (05) : 701 - 711
[37] Structure-Based Predictors of Resistance to the HIV-1 Integrase Inhibitor Elvitegravir
Masso, Majid
Chuang, Grace
Jain, Shinar
Hao, Kate
Vaisman, Iosif I.
BIOPHYSICAL JOURNAL, 2014, 106 (02) : 409A - 409A
[38] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
Roquebert, B.
Damond, F.
Collin, G.
Matheron, S.
Taieb, A.
Peytavin, Ct
Benard, A.
Campa, P.
Chene, G.
Brun-Vezinet, F.
Descamps, D.
ANTIVIRAL THERAPY, 2007, 12 (05) : S92 - S92
[39] Structure-based predictors of resistance to the HIV-1 integrase inhibitor Elvitegravir
Masso, Majid
Chuang, Grace
Hao, Kate
Jain, Shinar
Vaisman, Iosif I.
ANTIVIRAL RESEARCH, 2014, 106 : 5 - 12
[40] HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
Depatureaux, Agnes
Mesplede, Thibault
Quashie, Peter
Oliveira, Maureen
Moisi, Daniela
Brenner, Bluma
Wainberg, Mark
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 152 - 153

← 1 2 3 4 5 →